MiR-26 decreases atherosclerosis development in vivo by suppressing the expression of multiple genes, including ACC1, ACC2, ACLY, ACSL3, ACSL4, ALDH3A2, ALPL, BMP2, CD36, COL1A1, CPT1A, CTGF, DGAT2, EHHADH, FAS, FBP1, GATA4, GSK3β, G6PC, Gys2, HMGA1, HMGB1, LDLR, LIPC, IL-1β, IL-6, JAG2, KCNJ2, MALT1, β-MHC, NF-κB, PCK1, PLCβ1, PYGL, RUNX2, SCD1, SMAD1, SMAD4, SMAD5, SMAD7, SREBF1, TAB3, TAK1, TCF7L2, and TNF-α. Here, PLCB1 is linked to atherosclerosis.